ArticleCureus2025
Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) From Matched Related Donors in Pediatric Patients: Insights From a Single Center in the United Arab Emirates.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Allogeneic hematopoietic stem cell transplantation (HSCT) saves lives by treating a diverse range of pediatric conditions. Pediatric HSCT services began in the UAE in 2022. This study evaluates outcomes of the first 25 cases at Burjeel Medical City, Burjeel Cancer Institute, Abu Dhabi, following the establishment of the UAE's first pediatric bone marrow transplantation (BMT) unit. Method This retrospective study included children aged >30 days to <18 years who received HSCT from fully human leukocyte antigen (HLA)-matched related donors. Pre-transplant optimization and conditioning regimens were tailored to individual needs by a multidisciplinary team. Results The bone marrow served as the primary stem cell source in 96% of cases. Median engraftment times were 18 days for neutrophils and 15 days for platelets. Transplant-related mortality was 0%, with 4% graft failure and a 100% survival rate. Complications included bacterial sepsis (32%), acute graft-versus-host disease (GVHD) (20%), and chronic GVHD (12%). Conclusion Pediatric HSCT in the UAE has proven to be feasible and effective, offering a cost-efficient alternative to treatment abroad. It enhances access to advanced care within the region, marking a significant step forward in local pediatric healthcare and medical self-reliance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.